Hyperpolarized Xe129
Phase 2Small molecule
Hyperpolarized Xe129 is one of 207 small molecule programs targeting Lung Disease. It is currently in Phase 2.
6
Indications
10
Total Trials
8
Active Trials
206
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Hyperpolarized Xe129
UUniversity of Kansas Medical Center
Phase 2
Bnt162b2
BioNTechPreclinical
Activella
Eli LillyPreclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Rayaldee
OOrganon and Co
Preclinical
Nadroparin
GSKPreclinical
Statins
SanofiPreclinical
Glucocorticoid
AbbViePreclinical
HB-Admscs
HHope Biosciences Research Foundation
Preclinical
Olokizumab
UCBPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pulmonary Disease1 trial
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
Recruiting·—·Phase 1·NCT04624490·260 enrolled
Pulmonary Arterial Hypertension1 trial
5 more indications
Lung Disease1 trial
Regional Monitoring of CF Lung Disease
Recruiting·—·Phase 1·NCT06339593·60 enrolled
CAR1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hyperpolarized Xe129. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details